title: [C-reactive protein changes with antihypertensive and statin treatment].
abstract: OBJECTIVE
  The aim of this study was to evaluate the modifications of high sensitivity C-reactive protein (CRP) with antihypertensive and statin treatment in a hypertensive population with a wide range of coronary risks (CR).
  
  
  METHODS
  Retrospective follow-up study in 665 hypertensive patients: 556 (52% male) without dyslipidemia and CR (Framingham at 10 years) of 8.3 (7.6) as a control group (C) and 109 (61% male) with dyslipidemia and CR of 13.1 (8.8) who were treated with statins (T). Statins treatment was established according to NCEP-ATP-III. In both groups, the antihypertensive treatment was optimized in order to achieve blood pressure (BP) control (< 140/90 mmHg). A lipid profile and high sensitivity CRP (analyzed by nephelometry) was performed at the beginning and at the end of follow up [14.3 (3.6) months].
  
  
  RESULTS
  CRP levels were reduced in the T group -0.17 (0.2) mg/L vs. 0.14 (0.09) mg/L (p = 0.003, Mann-Whitney) in C. The lessening of CRP was not related to the reduction of lipids levels: total cholesterol (r = 0.06; p = 0.49), LDL-C (r = 0.11; p = 0.24), triglycerides (r = -0.02; p = 0.81) (Spearman), or to the reduction of systolic BP (r = -0.07; p = 0.44) and diastolic BP (r = -0.121; p = 0.21). The T group was treated with more antihypertensive drugs than C (2.2 [2.3] vs. 2.5 [1.2]; p = 0.02). Patients treated with ECA inhibitors or angiotensin II antagonist showed a tendency to decreasing the CRP levels more (p = 0.08).
  
  
  CONCLUSIONS
  In hypertensive populations, statins induce a reduction of CRP levels. The reduction is not related to the lowering of lipids levels or BP values. The effect of statins on the reduction of CRP in hypertensive patients is not related to the lowering of lipids or BP.
authors.affiliation: Unidad de Hipertensión Arterial y Riesgo Vascular, Servicio de Medicina Interna, Hospital de Sagunto, Port de Sagunt, Valencia, Spain.
authors.forename: Enrique
authors.initials: E
authors.lastname: Rodilla
authors.forename: Ana
authors.initials: A
authors.lastname: Gómez-Belda
authors.forename: José A
authors.initials: JA
authors.lastname: Costa
authors.forename: Miriam
authors.initials: M
authors.lastname: Aragó
authors.forename: Amparo
authors.initials: A
authors.lastname: Miralles
authors.forename: Carmen
authors.initials: C
authors.lastname: González
authors.forename: José M
authors.initials: JM
authors.lastname: Pascual
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis*; D050171:Dyslipidemias / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein